zelquistinel

Phase 2Small molecule

SSyndeio Biosciences, Inc

zelquistinel is one of 49 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderRecruiting

Major Depressive DisorderPhase 2

Recruiting

Competition

Competitive Landscape

115 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

26 2

Ozempic

Novo Nordisk

Approved

2 3

Lunesta

Akero Therapeutics

Approved

3 4

Fanapt

VVanda Pharmaceuticals

Approved

1 5

Ativan

BBausch Health Americas, Inc.

Approved

—6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 7

Ketalar

Boehringer Ingelheim

Phase 3

5 8

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 9

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 10

Psilocybin

COMPASS Pathways

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Major Depressive Disorder

NCT06547489

Q2 2028

Phase 2Recruiting

Major Depressive Disorder

NCT07115329

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

A Phase 2, Multicenter, Randomized, Double-blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder in Adults

Recruiting·SSyndeio Biosciences, Inc·Phase 2·NCT06547489·164 enrolled

Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Recruiting·SSyndeio Biosciences, Inc·Phase 2·NCT07115329·164 enrolled

Tics1 trial

Pharmacokinetics of Zelquistinel in Fasted or Fed State

Active, not recruiting·SSyndeio Biosciences, Inc·Phase 1·NCT07099989·32 enrolled

Unspecified1 trial

Safety and Tolerability of Zelquistinel in Normal Human Volunteers

Completed·SSyndeio Biosciences, Inc·Phase 1·NCT04981561·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for zelquistinel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zelquistinel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zelquistinel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syndeio Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyndeio Biosciences, Inc

zelquistinel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Major Depressive Disorder2 trials

Tics1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News